Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Arthritis, Rheumatoid 4Lymphoma, Follicular 1

Interventions

Adalimumab 19Etanercept 16Methotrexate 11Infliximab 8tocilizumab 7Rituximab 7golimumab 6Abatacept 6tofacitinib 5Tumor Necrosis Factor Inhibitors 5olokizumab 4Certolizumab Pegol 4Antirheumatic Agents 3Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Arthritis, Rheumatoid × olokizumab × Clear all
NCT01242488 2024-07-17

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
221 enrolled

Arthritis, Rheumatoid

NCT03120949 2023-10-12

CREDO 4

R-Pharm

Phase 3 Completed
2,106 enrolled 30 charts
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT02760433 2023-09-21

CREDO 3

R-Pharm

Phase 3 Completed
368 enrolled 21 charts

Arthritis, Rheumatoid

NCT01463059 2013-03-25

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
119 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡